Healio Minute Podcast, Leukemia Edition: Top Headlines - Week of March 13, 2023
Click Here to Manage Email Alerts
In this edition, outpatient HSCT feasible for older adults; ponatinib for newly diagnosed Ph+ALL; iomab-B may increase transplant access in relapsed/refractory AML and more.
Read the full coverage here:
Outpatient HSCT feasible for older adults with AML, myelodysplastic syndrome
Ponatinib ‘should be considered a standard of care’ for newly diagnosed Ph+ALL
Iomab-B may increase transplant access, improve outcomes in relapsed/refractory AML
Living along US-Mexico border linked to higher risk for death among children with leukemia
Breyanzi study meets complete response endpoint for leukemia, lymphoma subgroup
References:
Castellanos MI, et al. Cancer. 2023;doi:10.1002/cncr.34636.
Gyurkocza B, et al. Abstract LBA3. Presented at: Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR, Feb. 15-19, 2023; Orlando.
Muffly L, et al. Abstract 86. Presented at: Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR, Feb. 15-19, 2023; Orlando.
Press Release
Collapse